RENFREW, Scotland – June 13, 2023 – Terumo Aortic, a division of Terumo Corporation, today announced the launch of the global Thoraflex™ Hybrid EXTEND Study, a post-market clinical study designed to further evaluate long-term outcomes associated with the Thoraflex Hybrid device.
The EXTEND Study will collect long-term clinical data across multiple international sites to build on the existing body of evidence supporting the Thoraflex Hybrid device's use in the treatment of complex aortic arch disease.
"The EXTEND Study reflects our ongoing commitment to generating robust, long-term clinical evidence for the Thoraflex Hybrid device," said a Terumo Aortic representative. "This study will help us continue to support surgeons and patients with confidence in this important treatment option."
The study is expected to enroll patients across multiple centers globally, further strengthening the clinical foundation for the Thoraflex Hybrid device in the treatment of complex aortic disease.
About Terumo Aortic
Terumo Aortic, a division of Terumo Corporation, designs, develops and manufactures a broad portfolio of stent-graft and surgical solutions for the treatment of aortic disease, serving physicians and patients worldwide.
